144 related articles for article (PubMed ID: 23127528)
1. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy.
Tsutsumi K; Kawamoto H; Hirao K; Sakakihara I; Yamamoto N; Noma Y; Fujii M; Kato H; Ogawa T; Ishida E; Kuwaki K; Nouso K; Okada H; Yamamoto K
Pancreatology; 2012; 12(5):409-16. PubMed ID: 23127528
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Boeck S; Wittwer C; Heinemann V; Haas M; Kern C; Stieber P; Nagel D; Holdenrieder S
Br J Cancer; 2013 Apr; 108(8):1684-94. PubMed ID: 23579210
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
[TBL] [Abstract][Full Text] [Related]
8. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract][Full Text] [Related]
9. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
10. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Stemmler J; Stieber P; Szymala AM; Schalhorn A; Schermuly MM; Wilkowski R; Helmberger T; Lamerz R; Stoffregen C; Niebler K; Garbrecht M; Heinemann V
Onkologie; 2003 Oct; 26(5):462-7. PubMed ID: 14605463
[TBL] [Abstract][Full Text] [Related]
11. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
[TBL] [Abstract][Full Text] [Related]
12. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Wong D; Ko AH; Hwang J; Venook AP; Bergsland EK; Tempero MA
Pancreas; 2008 Oct; 37(3):269-74. PubMed ID: 18815548
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Shiozawa S; Tsuchiya A; Kim DH; Ogawa K
Nihon Rinsho; 2006 Jan; 64 Suppl 1():297-300. PubMed ID: 16457270
[No Abstract] [Full Text] [Related]
14. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
15. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
17. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Boeck S; Schulz C; Stieber P; Holdenrieder S; Weckbach S; Heinemann V
Onkologie; 2007 Feb; 30(1-2):39-42. PubMed ID: 17264524
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
19. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
